TIGIT and LAG3 back in the spotlight at ASCO 2023
Phase I data reignite enthusiasm for checkpoint inhibitors, but will the results reproduce?
A pair of positive checkpoint inhibitor readouts due at ASCO 2023 is bringing much needed enthusiasm back to the immuno-oncology arena, keeping one compound in the running for a rare next-generation checkpoint inhibitor success story, and bringing new life to another.
In an American Society of Clinical Oncology abstract published on Thursday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported updated Phase I results for its LAG3 inhibitor fianlimab in combination with PD-1 inhibitor Libtayo cemiplimab to treat advanced melanoma. The combo appears to be effective beyond the first-line setting, including in patients treated with prior adjuvant or neoadjuvant PD-1 inhibitors. ...